Cancer is a leading cause of death in canines, with 1 in 4 dogs in the u.s Expected to be diagnosed with cancer in their lifetime.² 73% of pet owners are interested in having a cancer screening test for their pet—and now you can offer them one.³ the revolutionary technology behind idexx cancer dx testing detects a proprietary, circulating biomarker. Idexx laboratories shared earlier this month the launch of idexx cancer dx, a diagnostic panel with early detection of lymphoma in canine patients The new panel is an accessible blood test that can be added to the panels of sick pets and can be integrated into annual wellness screenings Idexx cancer dx costs as low as $15, providing professionals in the united states with actionable results. The nu.q canine cancer screening test, a diagnostic product manufactured by volition, is now available through idexx's u.s
Among the detected cancers are lymphoma, hemangiosarcoma and. Idexx unveils cancer dx™, a revolutionary $15 blood test for early lymphoma detection in dogs Technology enables affordable inclusion in preventive care profiles. It is most affordable when ordered in select profiles such as the ones listed below Idexx cancer dx with canine lymphoma will be available at the idexx reference laboratories in the u.s And canada in late march 2025
Volition, a multinational epigenetics company, announced today the availability of its nu.q vet cancer test through the idexx reference laboratory network in the us 1 tom butera, dvm, chief executive officer of volition veterinary diagnostics development llc, said Idexx is a global leader in.
OPEN
